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Abstract
Background: Sporadic inclusion body myositis (sIBM) is the most prevalent acquired muscle disease in the elderly.
sIBM is an intractable and progressive disease of unknown cause and without effective treatment. The etiology of
sIBM is still unknown; however, genetic factors, aging, lifestyles, and environmental factors may be involved. The
purpose of this study is to elucidate the cross-sectional profile of patients affected by sIBM in Japan.
Methods: We surveyed patient data for 146 cases diagnosed at a number of centers across Japan. We also issued a
questionnaire for 67 patients and direct caregivers to further elucidate the natural history of the disease.
Results: The mean age at the onset was 63.4 ± 9.2 years. The mean length of time from the onset to diagnosis was
55.52 ± 49.72 months, suggesting that there is a difficulty in diagnosing this disease with long-term consequences
because of late treatment. 73 % described the psychological/mental aspect of the disease. The most popular primary
caregiver was the patient’s spouse and 57 % patients mentioned that they were having problems managing the finances.
Conclusions: Through these surveys, we described the cross-sectional profiles of sIBM in Japan. Many patients described
psychological/mental and financial anxiety because of the aged profile of sIBM patients. The profiles of sIBM patients are
similar to those in Western countries.
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Background
Sporadic inclusion body myositis (sIBM) is the most com-
mon form of inflammatory myopathy in those over the
age of 50 years in Western countries [1–3]. Muscle weak-
ness and atrophy in the quadriceps, wrist flexor, and finger
flexors are typical neurological findings of sIBM. Muscle
biopsy typically reveals endomysial inflammation, invasion
of mononuclear cells into non-necrotic fibers, and rimmed
vacuoles, suggesting that inflammation and degeneration
are co-existed in the pathological mechanism. The preva-
lence in Caucasians ranges between 4.9 and 14.9 per mil-
lion but is only 1.07 in Turkey [4]. We previously
performed a retrospective survey of Japanese patients di-
agnosed with sIBM at the National Center of Neurology
and Psychiatry (NCNP) [5]. Even though the awareness of
sIBM by physician after 1970s contributes to the detection
bias, the increasing incidence of sIBM in Japan was
followed by the rapid change in dietary habits from a trad-
itional style to a Westernized diet after World War II, fas-
cinating the speculation that this change in dietary habits
might have an influence on the increasing number of pa-
tients with sIBM in Japan. Other groups have also re-
ported that the number of Japanese patients with sIBM
appears to have increased in recent years [6]. It is import-
ant to describe the detail of the clinical phenotypes in
Japan to elucidate the influence of dietary components
and genetic factors on the pathophysiology of sIBM. To
further understand the cross-sectional profile of patients
with sIBM in Japan, we surveyed patient data for 146 cases
gathered through a multicenter study in Japan for the first
time. We also performed a questionnaire survey of 67 pa-
tients and their direct caregivers to elucidate the natural
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history of the disease and aspects relating to anxiety.
Through these surveys, we described the cross-sectional




This was a cross-sectional study targeting patients with
sIBM registered at the collaborating institutes, which re-
ceived patients with myopathy in Japan. The detailed in-
formation was gleaned from 146 patients diagnosed
between January 2000 and December 2009 at 8 insti-
tutes, which were involved in the multicenter survey
(Fig. 1). Only patients with “definite” or “probable” sIBM
by clinical and biopsy criteria [3] were included in the
analysis. Biopsies were re-evaluated, and the pathological
diagnosis of sIBM was confirmed. All patient data in-
cluding clinical and pathological information were regis-
tered by doctors. Each of the attending neurologists
completed information pertaining to past medical
history, family history, and data from medical records
(biopsy findings, laboratory, and physiological data).
Questionnaire for patients and caregivers
We sent a postcard survey to neurologists in Japan ask-
ing whether the sIBM patients they are following could
cooperate with the questionnaire survey. We distributed
a registered self-administered questionnaire to the 67
patients, who agreed to reply through their attending
physician between October 2010 and January 2011, and
provided an explanation of the purpose of the study. It
was emphasized that participation in the study was
completely voluntary. Patients returned the question-
naires in sealed envelopes by themselves to ensure confi-
dentiality. The protocol for this study was approved by
the Ethics Committee of Tohoku University School of
Medicine. Items in the questionnaire included the past
medical history, complications, family medical history,
disease onset, ambulation status, and results of muscle
biopsy. The questionnaire included informations on
name, age, height, weight, and lifestyle. The structure of
the questionnaires for the patients and caregivers are
listed in Table 1.
Data analysis
Data were summarized using descriptive statistics, in-




To elucidate the cross-sectional profile of patients with
sIBM in Japan, we surveyed patient data for 146 cases in
Japan. The demographic profile of the patients is de-
scribed in Table 2.
In our cohort, the prevalence of male was higher than
that of females (male: n = 83, female n = 63) (Table 2). The
mean age at the onset was 63.43 ± 9.18 (range, 40–81)
years. Dysphagia was observed in 29 patients (23.2 %). The
Fig. 1 Patients’ distribution and collaborating institutes for Multicenter
survey. A total of 146 patients were included from 8 institutes
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involvement of flexor finger muscles was observed in 17
patients at the time of the survey. The most common ini-
tial symptom was weakness of the proximal lower mus-
cles, including quadriceps femoris (117 patients, 80 %)
(Fig. 2). Weakness of finger flexors (n = 9), shoulder girdle
muscle (n = 5), muscle pain (n = 3), general fatigue (n = 3),
and dysphagia (n = 5) were also noted. Apparent laterality
of the muscle weakness was described in 16 cases. Family
history of myopathy including familial inclusion body my-
opathy [7] was observed in 5 cases. Cognitive impairment
was not observed in these 146 cases.
The clinical diagnosis before muscle biopsy included
PM (n = 41), unclassified myopathy (n = 17), ALS (n = 6),
and LGMD (n = 9). The presumptive diagnosis of sIBM
was found in only 55 patients (Fig. 3).
In the laboratory data, serum creatine kinase level was
532.85 ± 371.33 (range, 30–2401). Antibodies against
hepatitis B virus (HBV) (n = 3), HCV (n = 16), and
HTLV-1 (n = 8) were observed. In muscle biopsy, nec-
rotic fibers were found in 88 cases. COX negative fibers
were found in 63 cases, although there are some COX
negative fibers in aged muscles. Cellular infiltration in
non-necrotic muscle fibers was observed in 67 cases. An
increased amount of adipose tissue was observed in 40
cases. Cellular infiltration in the endomysium was
present in 117 cases.
The mean length from disease onset to the time of
diagnosis was 55.52 ± 49.72 (range, 3–288) months, sug-
gesting that it is difficult to promptly diagnose this dis-
ease because of its clinical course.
In total, 24 % patients underwent an intervention of
some kind, whereas 76 % patients followed the natural
course of the disease. Among those who underwent
some type of intervention, prednisolone (40 %), intra-
venous immunoglobulin (IVIg; 31 %), intravenous
methylprednisolone (26 %), and vitamin B12 (VitB12;
3 %) were administered (Fig. 4). Depending on the sub-
jective judgment of the attending physician, 57 %
showed no change and 7 % showed worsening of the
disease among patients with treatment. Thirty-six
Table 2 Patients characteristics for Multicenter survey
Number Percent Mean ± SD Minimum Median Maximum
Sex Male 83 57
Female 63 43
Age at onset (years) 137 94 63.43 ± 9.18 40 65 81
Duration from onset to diagnosis (months) 143 98 55.52 ± 49.72 3 36 288
CK (IU/L) 141 97 532.85 ± 371.33 30 453 2401
The normal range for CK is 62–287 IU/L for males and 45–163 IU/L for females
Fig. 2 Initial symptoms of this cohort for Multicenter survey. The most common initial symptom was quadriceps weakness, including difficulty in
climbing stairs and standing up from the chair. Some patients had weakness of finger flexor muscles and dysphagia. A small number of patients
complained about muscle pain
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percent of patients were reported to show improvement
to some extent, even if only temporarily. The effect of
these treatments should be reexamined in the orga-
nized study design.
Questionnaire for patients and caregivers
To elucidate the natural history of the disease and to
measure emotions in both patients and caregivers, we is-
sued a questionnaire for both patients and caregivers of
these patients. The profile of the patients is described in
Table 3.
The mean age at examination was 73.20 ± 7.15 years.
The age at onset as described by the patients was
64.47 ± 8.21 years. The development and growth of
cases were unremarkable. There was a wide variety in
food preference, including meat, sweets, vegetables,
and fish (Fig. 5). The percentage of patients who
smoked was reported to be 54.5 %. The initial symp-
toms are similar to the survey findings obtained by the
neurologist. The duration of milestone symptoms after
the onset is described in Table 4. The inability to stand
independently occurred after an average of 4.6 years.
The average time of being wheelchair-bound was
7.3 years from the onset and that of being electrical
wheelchair-bound was 13.7 years. The average time
from onset to the inability to open a plastic bottle was
6.6 years. Furthermore, the time from onset until the
patients were unable to wash their own face was
7.2 years.
For questions relating to anxiety, 73 % described to
the psychological/mental aspect of the disease. The most
popular primary caregiver was the patient’s spouse
(Fig. 6). As sIBM tends to occur from mid-to-older age,
the partner of the patient often had no physical strength
and may have had disease. Some patients complained
about the bleak outlook of the sIBM therapy. With refer-
ence to the financial aspects of the disease and how it af-
fected the household, 57 % patients mentioned that they
were having problems managing the finances.
Discussion
We surveyed patient data for 146 cases diagnosed at a
number of centers across Japan to elucidate the cross-
sectional profile of patients affected by sIBM in Japan.
We also issued a questionnaire for 67 patients and direct
caregivers to further elucidate the natural history of the
disease. Through these surveys, we described the cross-
sectional profiles of sIBM in Japan for the first time in
the Asian countries. We found the same issues in the
clinical practices of sIBM in Japan similar to Western
countries.
Fig. 3 Presumptive diagnosis before muscle biopsy for the
Multicenter survey. The clinical diagnosis of sIBM was confirmed in
only 38 % patients. The others were PM (29 %), unclassified
myopathy (12 %), LGMD (6 %), and ALS (4 %)
Fig. 4 Interventions for this cohort for Multicenter survey. In total, 24 % patients underwent some type of intervention, whereas 76 % patients
were allowed to follow the natural course of disease. Among those who received some form of intervention, prednisolone (PSL; 40 %),
intravenous immunoglobulin (IVIg; 31 %), intravenous methyl-prednisolone (mPSL; 26 %), and vitamin B12 (VitB12; 3 %) were executed with
limited effect
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Interestingly, a rather high percentage of patients were
seropositive for HCV (n = 16) and HTLV-1 (n = 8) in our
multicenter survey, corroborating the interaction be-
tween viral infection and the pathophysiology of sIBM,
as mentioned previously. Eleven patients with HTLV-1–
associated IBM were reported in the endemic area in
Japan [8]. The prevalence of HTLV-1 infection in sIBM
is higher than in the general population, compared with
the prevalence in general in Japanese people aged 60 to
64 years in 2006–2007, which was estimated to be 1.5 %
in men and 1.7 % in women [9]. Moreover, Uruha et al.
reported that a significantly higher number of patients
with sIBM (28 %) had anti-HCV antibodies than patients
with polymyositis (4.5 %; odds ratio, 8.2) and the general
Japanese population in their 60s (3.4 %) [9]. A pathome-
chanistic link between sIBM and HTLV1/HCV infection
merits further research.
For the purpose of early intervention in clinical trials,
early diagnosis of disease is important. Some of the pa-
tients in our study visited several physicians and the
average time from date of onset to diagnosis was
55.52 months. Some patients show isolated weakness of
finger flexors 3 years after onset but were diagnosed
with sIBM in muscle biopsy 6 years after onset [10].
Some patients underwent repeat biopsy of the muscle
because of the lack of findings related to rimmed vacu-
oles or other pathological markers. It is important to
evaluate which muscle should be biopsied using CT and
MRI. Currently, the utility of a new auto-antibody tar-
geting cytosolic 5′-nucleotidase 1A (cN-1A) in the
serum of patients with sIBM has recently been published
[11]. The diagnostic utility for differentiating between
sIBM, other forms of myositis, and other neuromuscular
diseases requires further examination. Reliable positive
markers for sIBM are necessary for the early diagnosis in
future clinical trials.
As shown in Fig. 5, clinical diagnosis tends to be dif-
ferent from sIBM in early diagnosis. The importance of
muscle biopsy is integral to the correct diagnosis. A clin-
ical trial of bimagrumab is ongoing [12]. Transforming
growth factor beta superfamily signaling, at least
through ActRII, is implicated in the pathophysiology of
sIBM. The inhibition of ActRII increased muscle mass
and function in this pilot trial, thus, offering a potential
novel treatment of sIBM [13]. Benveniste et al. reported
that 71 (52 %) patients received immunosuppressive
treatments such as prednisolone in 91.5, and 64.8 %
were treated with other immunomodulatory drugs, in-
cluding IVIgs, methotrexate, or azathioprine, for a me-
dian duration of 40.8 months [14]. This study confirms
immunosuppressive treatments do not ameliorate the
natural course of disease, thus, confirming findings from
smaller studies. The decision to terminate conventional
immunosuppressive treatment might be considered if
there is no apparent beneficial effect after the trial, dur-
ing a certain period of therapy.
In one of the abovementioned studies [15], euthanasia
was requested by three patients, and in another three,
continuous deep sedation was applied. The fact that
end-of-life care interventions were used in six patients
(13 %) reflects the severe disability and loss of quality of
life at the end stage of this disease [15]. sIBM is a
chronic progressive disorder, leading to major disabilities
at the end stage of the disease because of extensive
muscle weakness. Our questionnaire survey also revealed
several qualitative aspects relating to caregivers who
were typically spouses, and the difficulty in managing
Table 3 Patients characteristics for questionnaire study
Number Percent Mean ± SD Minimum Median Maximum
Age at the survey (years) 67 100 73.20 ± 7.15 53 73 90
Sex Male 49 73
Female 18 27
Age at onset (years) 67 73 64.47 ± 8.21 40 65 80
Fig. 5 Preference of food in the questionnaire study. There was a
wide preference of food, including meat, sweets, vegetables,
and fish
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the disease because of its long duration (Fig. 6). Clearly,
this impacts upon caregivers who themselves require so-
cietal support.
It is notable that 73 % of survey respondents described
the anxiety and psychological/mental aspect of the dis-
ease. Developed countries, including Japan, have an aged
society, and at mid-to-older age the partners of sIBM pa-
tients often lack physical strength and may have a dis-
ease. Some patients complained about the bleak outlook
of sIBM therapy. A total of 57 % of patients mentioned
problems managing finances. In Japan, there was no fi-
nancial support for patients affected by sIBM at the time
of the questionnaire; support for patients with intract-
able disease started in 2015. It is highly important to
prepare social resources in developed countries for rare
intractable diseases, including sIBM.
The present study has several limitations. First, the
study used a retrospective and cross-sectional design,
which cannot determine causal relationships. A longitu-
dinal study should be conducted to address this issue.
One group performed a follow-up study of 64 patients
with sIBM who participated in a national epidemio-
logical study in the Netherlands [15]. Case histories were
recorded and manual and quantitative muscle tests as
well as laboratory tests were performed at baseline and
12 years (median) after the first outpatient visit. Forty-
six patients died during the follow-up period. The 15
surviving patients had a mean disease duration of
20 years. The mean decline in strength was recorded to
be between 3.5 and 5.4 % per year according to the man-
ual muscle testing and quantitative muscle testing cri-
teria, respectively. Disorders of the respiratory system
were the most common cause of death. In another study,
136 patients (57 % males; average age, 61 years at disease
onset) were included [14]. During their follow-up, 75 %
patients had significant walking difficulties and 37 %
used a wheelchair (after a median duration of 14 years
from the onset). Compared to these studies, a rather low
rate of patients with finger flexor weakness or asymmet-
ric weakness was described in our survey. This could be
because the weakness is masked by compensatory mech-
anisms by lumbricals/FDS or not noticed by physicians
without examining the FDP specifically. The cross-
sectional nature of our study might affect the lower rate
of symptoms. The overall demographic details of pa-
tients are similar between Japan and Western countries.
The other limitation of this study was that we should
have included in the questionnaires for both patients
and caregivers detailed questions on the functional abil-
ity to swallow [16] and the form of the consumed food
(e.g., whether the meal was minced) in the questionnaire
for both the patients and caregivers. Aspiration pneumo-
nia is the common complication for sIBM and can
sometimes be fatal. More detailed questions (e.g., how
much cheese was eaten per week) with annual follow-up
would be helpful in any future study.
Conclusion
Through our multicenter patient survey and caregiver
questionnaire, the phenotypes of sIBM in Japan are simi-
lar to those in Western countries at least through a
cross-sectional methodology. Many patients described
psychological/mental and financial anxiety because of
the aged profile of sIBM patients. A follow-up survey is
required to reveal the prospective natural history of this
disease in Japan.
Abbreviation
cN-1A: Cytosolic 5′-nucleotidase 1A; FDP: Flexor digitorum profundus;
IVIg: Intravenous immunoglobulin; PSL: Prednisolone; sIBM: Sporadic
inclusion body myositis
Table 4 Milestones from questionnaire study
Unable to stand up
without assistance
Wheelchair bound Electric wheel chair Unable to open bottle Unable to wash face
Number of patients 53 23 6 43 12
Average duration (years) 4.6 7.3 13.7 6.6 7.2
SD 4.4 4.9 7.3 5.9 4.3
Fig. 6 Patient caregiver results from the questionnaire study. The most
popular primary caregiver was the spouse of the patient (69 %)
Suzuki et al. Orphanet Journal of Rare Diseases  (2016) 11:146 Page 6 of 7
Acknowledgments
We thank the patients and caregivers for their participation and neurologists
for their assistance in data collection. We also thank Naoko Shimakura, Yoko
Kanamori, Michiko Yoshida, and Naoko Arai for assistance with data
acquisition.
Funding
This study was supported by an Intramural Research Grant (26–7, 26–8) for
Neurological and Psychiatric Disorders through the NCNP; the grant on
Research on Rare and Intractable Diseases (H26-intractable disease 037 and
082) from the Ministry of Health, Labour and Welfare of Japan; the Ministry
of Health, Labour and Welfare of Japan (H21-nanchi-ippan-024, H22-nanchi-
ippan-117, H24-nanchi-ippan-028, H26-nanchitou(nan)-ippan-079); Health
and Labour Sciences Research Grants for Comprehensive Research on
Persons with Disabilities from Japan Agency for Medical Research and
Development (15Adk0310043h0002); Grants-in-Aid for research on rare and
intractable diseases; and Grant-in-Aid for Challenging Exploratory Research
(26670436) from the Japanese Ministry of Education, Culture, Sports, Science
and Technology.
Availability of data and materials
The questionnaire outline used to perform this survey is available in Table 1.
Please contact author for data requests.
Authors’ contributions
NS carried out the analysis of patients data and drafted the manuscript.
MM-Y, SY, SN, K-yM, YI, NM, EK, HK, TK, IH, RK, HO, MK, HW, and TT gathered
patients’ data. MT and RI analyzed muscle biopsy. NS, MM-Y, IN and MA
conceived of the study and participated in its design and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All protocols were approved by the ethics committee of Tohoku University
(No. 2009–292, 2014-1-358).
Author details
1Department of Neurology, Tohoku University Graduate School of Medicine,
1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan. 2Department of
Neurology, National Center Hospital, National Center of Neurology and
Psychiatry (NCNP), Tokyo, Japan. 3Department of Neurology, Graduate School
of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto,
Japan. 4Department of Neurology, Osaka City General Hospital, 2-13-22
Miyakojima hondoori, Miyakojima-ku, Osaka, Japan. 5Department of
Neurology, Wakayama Medical University, Wakayama, Japan. 6Department of
Neurology and Geriatrics, Kagoshima University Graduate School of Medical
and Dental Sciences, Kagoshima, Japan. 7Department of Clinical
Neuroscience, Institute of Biomedical Sciences, Tokushima University
Graduate School, Tokushima, Japan. 8Department of Neurology, Kansai
Medical University, 2-5-1, Shin-machi, Hirakata, Osaka, Japan. 9Department of
Neurology, National Hospital Organization Sendai-Nishitaga National Hospital,
Sendai, Japan. 10Department of Neuromuscular Research, National Institute of
Neuroscience, Tokyo, Japan. 11Department of Genome Medicine
Development, Medical Genome Center, National Center of Neurology and
Psychiatry (NCNP), Tokyo, Japan.
Received: 20 February 2016 Accepted: 11 October 2016
References
1. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts.
J Neurol Neurosurg Psychiatry. 2009;80(11):1186–93.
2. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative
muscle disease associated with intra-muscle fiber multi-protein aggregates,
proteasome inhibition, endoplasmic reticulum stress and decreased
lysosomal degradation. Brain Pathol. 2009;19(3):493–506.
3. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic
concepts and diagnostic and therapeutic approaches. Lancet Neurol.
2007;6(7):620–31.
4. Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL.
Prevalence of sporadic inclusion body myositis and factors contributing to
delayed diagnosis. J Clin Neurosci. 2008;15(12):1350–3.
5. Suzuki N, Aoki M, Mori-Yoshimura M, Hayashi YK, Nonaka I, Nishino I.
Increase in number of sporadic inclusion body myositis (sIBM) in Japan.
J Neurol. 2012;259(3):554–6.
6. Nakanishi H, Koike H, Matsuo K, Tanaka F, Noda T, Fujikake A, et al.
Demographic features of Japanese patients with sporadic inclusion body
myositis: a single-center referral experience. Intern Med. 2013;52(3):333–7.
7. Tateyama M, Saito N, Fujihara K, Shiga Y, Takeda A, Narikawa K, et al.
Familial inclusion body myositis: a report on two Japanese sisters. Intern
Med. 2003;42(10):1035–8.
8. Matsuura E, Umehara F, Nose H, Higuchi I, Matsuoka E, Izumi K, et al.
Inclusion body myositis associated with human T-lymphotropic virus-type I
infection: eleven patients from an endemic area in Japan. J Neuropathol
Exp Neurol. 2008;67(1):41–9.
9. Uruha A, Noguchi S, Hayashi YK, Tsuburaya RS, Yonekawa T, Nonaka I, et al.
Hepatitis C virus infection in inclusion body myositis: A case-control study.
Neurology. 2016;86(3):211–7.
10. Suwa Y, Suzuki N, Soga T, Harada R, Shibui A, Kuroda H et al. Sporadic
inclusion body myositis manifesting as isolated muscle weakness of finger
flexors for 3 years after the onset. Internal medicine (in press).
11. Herbert MK, Pruijn GJ. Novel serology testing for sporadic inclusion body
myositis: disease-specificity and diagnostic utility. Curr Opin Rheumatol.
2015;27(6):595–600.
12. Alfano LN, Lowes LP. Emerging therapeutic options for sporadic inclusion
body myositis. Ther Clin Risk Manag. 2015;11:1459–67.
13. Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et
al. Treatment of sporadic inclusion body myositis with bimagrumab.
Neurology. 2014;83(24):2239–46.
14. Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T,
et al. Long-term observational study of sporadic inclusion body myositis.
Brain. 2011;134(Pt 11):3176–84.
15. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A
12-year follow-up in sporadic inclusion body myositis: an end stage with
major disabilities. Brain. 2011;134(Pt 11):3167–75.
16. Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting
dysphagia in inclusion body myositis. J Neurol. 2009;256(12):2009–13.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Suzuki et al. Orphanet Journal of Rare Diseases  (2016) 11:146 Page 7 of 7
